Celgene acquires Juno Therapeutics for $9bn

By Catherine Sturman
Share
Following on from its acquisition of Impact Biomedicines for $7 billion, biopharmaceutical company Celgene has now acquired Juno Therapeutics for $9 bil...

Following on from its acquisition of Impact Biomedicines for $7 billion, biopharmaceutical company Celgene has now acquired Juno Therapeutics for $9 billion. The merger will see the company work to join Gilead and Novartis in the development of CAR (chimeric antigen receptor) and TCR (T cell receptor), becoming CAR-T therapeutics.

The process encompasses the extraction of a patient’s immune cells, which are then modified to attack cancer cells when reinserted into the patient.

Juno is a pioneer in the development of CAR-T therapeutics with a broad, novel portfolio evaluating multiple targets and cancer indications. Adding to Celgene’s lymphoma program, JCAR017 represents a potentially best-in-class CD19-directed CAR T currently in a pivotal program for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL).

Regulatory approval for JCAR017 in the U.S. is expected in 2019 with potential global peak sales of approximately $3 billion.

“The acquisition of Juno builds on our shared vision to discover and develop transformative medicines for patients with incurable blood cancers,” explained Mark J. Alles, Celgene’s Chief Executive Officer.

See also

“Juno’s advanced cellular immunotherapy portfolio and research capabilities strengthen Celgene’s global leadership in haematology and adds new drivers for growth beyond 2020.”

JCAR017 is expected to add approximately $3 billion in peak sales and significantly strengthen Celgene’s lymphoma portfolio, whereas JCARH125 will enhance Celgene’s campaign against BCMA (B-cell maturation antigen), a key target in multiple myeloma

The acquisition will also add a novel scientific platform and scalable manufacturing capabilities which will complement Celgene’s leadership in haematology and oncology.

In collaboration with Juno’s team in Seattle, Celgene plans to expand its existing centre of excellence for immuno-oncology translational medicine by leveraging Juno’s research and development facility in Seattle, WA as well as Juno’s manufacturing facility in Bothell, WA.

Share

Featured Articles

National Insurance: The Backbone of UK's Social Security

The UK's social security system is upheld by National Insurance (NI), a mandatory contribution, affecting most workers and employers. Here’s how it works

Lifetime of Achievement: Noel Anderson, American Red Cross

We celebrate Noel Anderson’s dedication to nonprofit humanitarianism & his leadership with the American Red Cross and beyond, at Sustainability LIVE London

Schneider Electric Powers Healthcare Facilities with Solar

Schneider Electric’s solar solutions are bringing healthcare to millions across Africa and India, as the company seeks to revolutionise rural healthcare

Apollo Hospitals’ Q2 Net Profit Soars by 63%

Hospitals

The Future of Cell Therapy for Thermo Fisher & Novo Nordisk

Medical Devices & Pharma

TikTok's Role in Healthcare: Safeguarding to Misinformation

Technology & AI